ArticleCNS neuroscience & therapeutics2019
Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas.
Article in CNS neuroscience & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Comprehensive analysis ofTranslational andrology and urology · 2024Article
- GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas.Cell death & disease · 2024Article
- High Expression of PXMP4 in Hepatocellular Carcinoma Tissues.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- GINS2 promotes the progression of human HNSCC by altering RRM2 expression.Cancer biomarkers : section A of Disease markers · 2024Article
- Estimating disease-free survival of thyroid cancer based on novel cuprotosis-related gene model.Frontiers in endocrinology · 2023Article
- Go-Ichi-Ni-San 2: A potential biomarker and therapeutic target in human cancers.World journal of gastrointestinal oncology · 2022Review
- E2F1-mediated GINS2 transcriptional activation promotes tumor progression through PI3K/AKT/mTOR pathway in hepatocellular carcinoma.American journal of cancer research · 2022Article
- GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.CNS neuroscience & therapeutics · 2022Article
- Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.Computational and mathematical methods in medicine · 2022Article
- GINS2 affects cell proliferation, apoptosis, migration and invasion in thyroid cancer via regulating MAPK signaling pathway.Molecular medicine reports · 2021Article
- GINS2 was regulated by lncRNA XIST/miR-23a-3p to mediate proliferation and apoptosis in A375 cells.Molecular and cellular biochemistry · 2021Article
- Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.Frontiers in immunology · 2021Article
- Identification of Hub Genes as Potential Prognostic Biomarkers in Cervical Cancer Using Comprehensive Bioinformatics Analysis and Validation Studies.Cancer management and research · 2021Article
- GINS2 affects cell viability, cell apoptosis, and cell cycle progression of pancreatic cancer cells via MAPK/ERK pathway.Journal of Cancer · 2020Article
- Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.Journal of ovarian research · 2019Article
- Analysis of functional hub genes identifies CDC45 as an oncogene in non-small cell lung cancer - a short report.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas.CNS neuroscience & therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn this study, we examined the expression of GINS2 in glioma and determined its role in glioma development.
methodsThe protein expression of GINS2 was assessed in 120 human glioma samples via immunohistochemistry. Then, we suppressed the expression of GINS2 in glioma cell strains U87 and U251 using a short hairpin RNA lentiviral vector. In addition, RNA sequencing and bioinformatics analysis were performed on glioma cells before and after GINS2 knockdown. Subsequent co-immunoprecipitation and western blot experiments indicated possible downstream regulatory molecules.
resultsThe present results showed that GINS2 can accelerate the growth of glioma cells, whereas the suppression of GINS2 expression decreased the proliferation and tumorigenicity of glioma cells. Mechanism research experiments proved that GINS2 can block the cell cycle by regulating certain downstream molecules, such as MCM2, ATM, and CHEK2.
conclusionGINS2 is closely related to the occurrence and development of glioma, and is likely to become a prognostic marker for glioma patients, as well as a potential therapeutic target in the treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.